


PERSONAL INFORMATION



Maria Vertzoni

Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis, 15784 Zografou, Greece

+30 210 7274445 +30 693 7198260

vertzoni@pharm.uoa.gr

Sex Female | Date of birth 08/11/70 | Nationality Greece

WORK EXPERIENCE

- | | |
|------------------------|---|
| 2026 - Current | Professor in Pharmaceutical Technology and Biopharmaceutics
Department of Pharmacy, National and Kapodistrian University of Athens (NKUA), Greece |
| 2022 – 2026 | Associate Professor in Pharmaceutical Technology and Biopharmaceutics
Department of Pharmacy, NKUA, Greece |
| 2017-2022 | Assistant Professor in Pharmaceutical Technology and Biopharmaceutics
Department of Pharmacy, NKUA, Greece |
| 2014-2017 | Laboratory and Teaching Personnel
Department of Pharmacy, NKUA, Greece |
| January-February 2008 | Visiting Scientist
Research and Development Department, Astra-Zeneca, Gothenburg, Sweden
Evaluation of degradation kinetics of APIs under anaerobic conditions |
| 2007-2014 | Laboratory Personnel
Department of Pharmacy, NKUA, Greece |
| November-December 2007 | Visiting Scientist
Research and Development Department, EURAND, Milan, Italy
Biorelevant dissolution tests |
| 2005-2011 | Adjunct Lecturer (Presidential Decree 407/80)
Department of Pharmacy, NKUA, Greece |

EDUCATION AND TRAINING

- | | |
|-----------------------|---|
| 2014-2016 | Master of Sciences Medical and Pharmaceutical Statistics
Department of Statistics, School of Information, Sciences and Technology, Athens University of Economics and Business |
| November 2009 | Research Fellow
Institute of Pharma Technology and Biotechnology, University of Applied Sciences Northwestern Switzerland, Basel, Switzerland
• Permeability experiments using Ca, co-2 cell lines and PAMPA |
| October-December 2000 | Research Fellow
Laboratory of Pharmacokinetics, Université de la Méditerranée, Aix-Marseille II, France
• Application of Matlab® software in the comparison of drug vs. time data sets with indices |
| 1999-2004 | Doctor of Philosophy Pharmaceutical Sciences
Department of Pharmacy, NKUA, Greece |

1996-1998 **Master of Sciences | Analytical Chemistry**
Department of Chemistry, NKUA, Greece

1989-1995 **Bachelor of Sciences | Chemistry**
Department of Chemistry, NKUA, Greece

Mother tongue(s)

Greek

Other language(s)

English

French

Italian

UNDERSTANDING		SPEAKING		WRITING
Listening	Reading	Spoken interaction	Spoken production	
C2	C2	C2	C2	C2
C2	C2	C2	C2	C2
C1	C1	C1	B2	B2

Organisational / managerial skills

Experience in managing research and training activities acquired through the coordination of various EU and industry funded programs and acting as principal advisor of 3 completed Doctoral Theses and 14 undergraduate/postgraduate theses.

Job-related skills

Designing and performing in vitro methodologies for the evaluation of drug products and clinical studies in healthy adults and geriatric population

Driving licence

B

ADDITIONAL INFORMATION

Publications and citations

<https://scholar.google.com/citations?user=jpTo1soAAAAJ&hl=el&oi=ao>

Projects

Principal Investigator

Special Account for Research, NKUA, 2018 | NKUA project number 56.90.15744
Financial support for newly elected members.
Budget: 5.000 €

Novartis, Switzerland, 2019-2020 | NKUA project number 56.90.16235
Investigation of the usefulness of BioGIT in the comparison of the intraluminal performance of various products and doses of Novartis internal drug against existing in vivo data in adults.
Budget: 49.140 €

Novartis, Switzerland, 2019-2021 | NKUA project number 56.90.16304
Evaluation of the impact of bacterial activity in the lower intestine on the clinical performance of LCZ696 based on data in optimized human fecal material. Biorelevant dissolution testing of LCZ modified products using the USP IV apparatus.
Budget: 167.640 €

European Training Network, Marie Skłodowska-Curie actions | NKUA project number 70/3/16868
European Union's Horizon 2020 Research and Innovation Programme.
Drug Absorption in Geriatric Patients and Older People: a training network innovating drug development for the advanced age population, AGEPOP, (<http://www.agepop.eu>).
Grant Agreement No. 956146, 2021-2024 | Coordinator: NKUA
Total budget: 2.790.443,74 € | Budget (NKUA): 906.034,74 €

Novartis, Switzerland, 2023-2024 | NKUA project number 56.90.20391
On the usefulness of BioGIT in the evaluation of the intraluminal performance of different drug products and doses of a Novartis active pharmaceutical ingredient (Compound B) in comparison with data in healthy adults.
Budget: 48.000 €

Novartis, Switzerland, 2024-2026 | NKUA project number 56.90.21261
Intraluminal characteristics and drug disposition in the upper gastrointestinal lumen after a standard low-calorie low-fat meal with the aim to optimize the biorelevant media testing conditions.
Budget: 200.000 CHF

Novartis, Switzerland, 2026-2027 | NKUA project number 56.90.60029
Characterisation of the duodenal fluid concerning pH, buffer capacity, osmolality, and concentrations of bile salts, phospholipids, and lipids collected from the 24 patients in the 5-12 years old paediatric population via clinical endoscopies
Budget: 60.000 €

Participation

GlaxoWellcome Research & Development, United Kingdom, 1999-2001 (NKUA 70/3/2014).
Predicting the oral absorption of poorly soluble drugs.

General Secretariat of Research and Technology & Lavipharm S.A., 1/12/1999–31/5/2001 (NKUA 70/3/4942)
Phytochemical characterization and bioavailability of ingredients from Greek varieties of olive trees, grapes and tomatos.

General Secretariat of Research and Technology & Galenica S.A., 1/6/2001-31/8/2003 (NKUA 70/3/6217).
Development of bioenabling formulation: using grapefruit components.

Adelco S.A., Greece, 1/7/2004-30/9/2004, (NKUA 70/3/7330).
Evaluation of the absorption of calcium from pharmaceutical products.

Kleva S.A., Greece, 1/7/2004-30/11/2004 (NKUA 70/3/7450).
Evaluation of the absorption of hesperidin and diosmin.

Pliva, Croatia, 15/9/2004-15/3/2005 (NKUA 70/3/7472).
Dissolution media composition, dissolution characteristics and evaluation of the absorption of one weak base: free form vs. two salts.

Merck KGaA, Germany, 01/03/05-31/07/05 (NKUA 70/3/8073).
Oral absorption of various pharmaceutical products of EMD 57033 in dogs.

European Social Fund and National Resources (EPEAEK II) PYTHAGORAS, the (Greek) State Scholarships Foundation, 01/03/05-31/12/06 (NKUA 70/3/7967). Investigation of intestinal absorption of APIs from biodegradable lipids after administration to adults.

Astra-Zeneca, Sweden, 2006-2009 (NKUA 70/3/6268).
Physicochemical characterization of contents of the ascending colon of healthy adults and of patients with ulcerative colitis.

Rohm, Germany, 01/05/07-01/12/07 (NKUA 70/3/9292).
Absorption of felodipine after oral administration of various pharmaceutical products to dogs.

Goethe University, Frankfurt, Germany, 2008-2009 (NKUA 70/3/9630).
Determination of lipids in the contents of upper small intestine of healthy adults.

GlaxoSmithKline plc, United Kingdom, 2008-2010 (NKUA 70/3/9555). In vivo evaluation of the precipitation of weak bases in the intestinal lumen of healthy adults.

Merck Sharp & Dohme Corp., USA, 2011-2012 (NKUA 56.90.11372).
Development of in vitro methods for predicting differences between salts and free acids or free bases of APIs.

European Union's Seventh Framework Programme (FP7/2007-2013),
Grant Agreement No. 115369, 2012-2017 (NKUA 70/3/11819).
Oral Biopharmaceutics Tools" (OrBiTo), Innovative Medicines Initiative (IMI) (<http://www.imi.europa.eu>).

Merck Sharp & Dohme Corp., USA, 2013-2015 (NKUA 56.90.11372).

Development of in vitro methods for predicting dissolution kinetics of weak bases and their salts under achlorhydric or hypochlorhydric conditions.

Bayer Pharma AG, Germany, 2014-2016 (NKUA 56.90.12583).
Evaluation of stability of selected BAYER compounds and of generic compounds in contents of lower intestine and in optimized human fecal material from healthy adults.

Merck Sharp & Dohme Corp., USA 2016-2018 (NKUA 56.90.11372). Evaluation of precipitation in human intestinal fluids: Focus to weak bases and to solid dispersions.

European Training Network (ETN), Marie Skłodowska-Curie actions (<http://www.pearl.eu>),
European Union's Horizon 2020 Research and Innovation Programme.
Grant Agreement No. 674909, 2016-2020 (NKUA 70/3/12501).
Pharmaceutical Education And Research with Regulatory Links" (PEARRL).

Merck, Germany 2018-2020, (NKUA 56.90.15463).
Evaluation of the usefulness of BioGIT model in the comparison intraluminal performance of orally administered Merck KGaA active pharmaceutical ingredients formulated as conventional and/or bioenhanced dosage forms.

Hellenic Foundation for Research and Innovation, 2019-2022 (Athena Research and Innovation Center).
Optimizing drug development by modeling and simulation approaches.

Unipharm, Greece 2020-2021 (NKUA 56.90.17118).
In vitro investigations on prototype mesalamine formulations aiming at the development of an orally administered modified release product.

Janssen, Belgium 2020-2021 (NKUA 56.90.17070).
Evaluation of the impact of bacterial activity in the lower intestine on the clinical performance of selected compounds based on data in optimized human fecal material.

Janssen, Belgium 2020-2021 (NKUA 56.90.17311).
Implementation at Janssen and evaluation of the usefulness of BioGIT model.

Merz Consumer Care GmbH, Germany 2020-2021 (NKUA 56.90.16588).
Clinical effectiveness of a pH increasing test product.

European Training Network (ETN), Marie Skłodowska-Curie actions (<http://www.colotan-etn.eu>).
European Union's Horizon 2020 Research and Innovation Programme.
Grant Agreement Grant Agreement No. 956146, 2021-2024, (NKUA 70/3/16917).
Boosting advanced doctoral training in innovative colon targeting drugs (COLOTAN).

European Training Network (ETN), Marie Skłodowska-Curie actions (<http://www.inpharma-network.eu>).
European Union's Horizon 2020 Research and Innovation Programme.
Grant Agreement No. 956146, 2021-2024 (NKUA 70/3/16971).
A fully integrated, animal-free, end-to-end modelling approach to oral drug product development" (InPharma).

Work and Competency Area Taxonomy of Functions & Domains		
FUNCTION / DOMAIN category - EN	Catégorie FONCTION / DOMAINE - FR	Your domain
STATISTICS and general MATHEMATICS	STATISTIQUES et MATHÉMATIQUES générales	
ANALYSIS and INTELLIGENCE	ANALYSE et RENSEIGNEMENT	
KNOWLEDGE MANAGEMENT & ECONOMY	GESTION des CONNAISSANCES & ÉCONOMIE de la CONNAISSANCE	
SCIENCE and RESEARCH	SCIENCE et RECHERCHE	
INNOVATION and CREATIVITY	INNOVATION et CRÉATIVITÉ	
CLIMATE, ENVIRONMENT and NATURAL RESOURCES	CLIMAT, ENVIRONNEMENT et RESSOURCES NATURELLES	
AGRICULTURE	AGRICULTURE	
FORESTRY	SYLVICULTURE	
FISHERY and MARITIME AFFAIRS	PÊCHE et AFFAIRES MARITIMES	
ENTERPRISE and MARKETS	ENTREPRISES et MARCHÉS	
COMMERCE (general)	COMMERCE (général)	
COMPETITION and CONSUMERS	CONCURRENCE et CONSOMMATEURS	
TRADE	COMMERCE	
TAXATION and CUSTOMS	FISCALITÉ et DOUANE	
ECONOMICS	ÉCONOMIE	
FINANCIAL INSTRUMENTS and INSTITUTIONS, incl BANKING	INSTRUMENTS FINANCIERS et INSTITUTIONS FINANCIÈRES, y compris les BANQUES	
BUDGET, FINANCE, CONTRACTS and ACCOUNTING	BUDGET, FINANCES, CONTRATS et COMPTABILITÉ	
POLICY	POLITIQUE	
LAW	DROIT	
LAW ENFORCEMENT	APPLICATION du DROIT	
LEGAL OFFENSE, CRIMINOLOGY and FORENSICS	INFRACTIONS à la LOI, CRIMINOLOGIE et SCIENCES FORENSIQUES	
ANTI-FRAUD	LUTTE contre la FRAUDE	
INVESTIGATION, COMPLIANCE and INFRINGEMENT HANDLING	ENQUÊTES, VÉRIFICATION de CONFORMITÉ et TRAITEMENT des INFRACTIONS	
AUDIT, CONTROL and INSPECTION	AUDIT, CONTRÔLE et INSPECTION	
EVALUATION and QUALITY MANAGEMENT	ÉVALUATION et GESTION de la QUALITÉ	
PROGRAM / PROCESS / PROJECT MANAGEMENT	GESTION de PROJETS, PROGRAMMES et PROCESSUS	
OPERATIONAL and ADMINISTRATIVE SUPPORT and RESOURCES	SUPPORT et RESSOURCES OPÉRATIONNELS et ADMINISTRATIFS	
LOGISTIC SUPPORT	SUPPORT LOGISTIQUE	
TECHNICAL and LABORATORY WORK	TRAVAUX TECHNIQUES et TRAVAUX en LABORATOIRE	
TECHNOLOGIES and ENGINEERING in SCIENCE and INDUSTRY	TECHNOLOGIES et INGÉNIERIE dans les SCIENCES et l'INDUSTRIE	
ENERGY POLICIES and TECHNOLOGIES	POLITIQUES de l'ÉNERGIE et TECHNOLOGIES	
TRANSPORT (incl logistics)	TRANSPORT (y compris logistique)	
BUILDINGS and SUPPLIES (incl logistics)	BÂTIMENTS et FOURNITURES (y compris logistique)	
SAFETY, SECURITY and CRISIS MANAGEMENT	SÉCURITÉ, SÛRETÉ et GESTION de CRISE	
HEALTH	SANTÉ	
EMPLOYMENT (EU/national/regional level)	EMPLOI (UE/national/régional)	
LABOUR LAW	DROIT du TRAVAIL	
HUMAN RESOURCE MANAGEMENT	GESTION des RESSOURCES HUMAINES	
EDUCATION and TRAINING (general)	ÉDUCATION et FORMATION (général)	
CULTURE, HUMANITIES, PHILOSOPHY and HISTORY	CULTURE, SCIENCES HUMAINES, PHILOSOPHIE et HISTOIRE	
LANGUAGES and LINGUISTICS	LANGUES et LINGUISTIQUE	
MULTILINGUAL and TERMINOLOGY RESOURCES	RESSOURCES MULTILINGUES et TERMINOLOGIQUES	
CLASSIFICATION, STANDARDS and NOMENCLATURES	CLASSIFICATION, NORMES et NOMENCLATURES	
INFORMATION and DOCUMENT MANAGEMENT	INFORMATION et GESTION des DOCUMENTS	
COMMUNICATION and PUBLICATION	COMMUNICATION et PUBLICATION	
TELECOMMUNICATION and TELEPHONY	TÉLÉCOMMUNICATIONS et TÉLÉPHONIE	
INFORMATION and COMMUNICATION TECHNOLOGIES	TECHNOLOGIES de l'INFORMATION et de la COMMUNICATION	
IT TOOLS for SPECIFIC APPLICATION AREAS	OUTILS INFORMATIQUES pour des DOMAINES d'APPLICATION SPÉCIFIQUES	
(APPLIED) COMPUTER SCIENCE	INFORMATIQUE (APPLIQUÉE)	
INTER-INSTITUTIONAL RELATIONS	RELATIONS INTERINSTITUTIONNELLES	
JUSTICE and HUMAN/CIVIL RIGHTS	JUSTICE et DROITS HUMAINS/CIVILS	
SOCIAL SCIENCES and POLICIES	SCIENCES et POLITIQUES SOCIALES	
HUMAN GEOGRAPHY	GÉOGRAPHIE HUMAINE	
COHESION POLICY (EU/national level)	POLITIQUE de COHÉSION (UE/national/régional)	
REGIONAL POLICY (EU/national level)	POLITIQUE RÉGIONALE (UE/national/régional)	
DEMOGRAPHY and MIGRATION	DÉMOGRAPHIE et MIGRATION	
EXTERNAL RELATIONS	RELATIONS EXTÉRIEURES	